The evaluation of neutropenia is dictated by the acuity of the clinical presentation and the duration, age, and clinical status of the patient. In this review, we provide a practical approach to the evaluation of the adult patient with neutropenia, with the major focus on the evaluation of ...
To evaluate the utilization and value of this test with our patient population (a hematopoietic stem cell transplant center), we reviewed all galactomannan ... DC Zedek,MB Miller - 《Journal of Clinical Microbiology》 被引量: 52发表: 2006年 General practitioners' approach to hypertension in urban...
Gibson C, Berliner N: How we evaluate and treat neutropenia in adults . Blood. 2014, 124:1251-1258. 10.1182/blood-2014-02-482612Gibson C, Berliner N. 2014. How we evaluate and treat neutro- penia in adults. Blood 124:1251-8. quiz 1378....
or high-risk chromosomal abnormalities) to evaluate the safety and efficacy of the two agents in these difficult-to-treat patients and to provide treatment... M A,Dimopoulos,Sonneveld,... - 《Annals of Oncology Official Journal of the European Society for Medical Oncology》 被引量: 4发表: ...
Therefore, it is critical to re-evaluate the diagnosis during the course of the disease, especially in patients who respond poorly to treatment and cases with new symptoms, signs, and new laboratory findings. According to the disease duration, ITP can be divided into newly diagnosed (< 3 ...
or are eventually diagnosed with thrombocytopenia secondary to connective tissue diseases such as systemic lupus erythematosus (SLE). Therefore, it is critical to re-evaluate the diagnosis during the course of the disease, especially in patients who respond poorly to treatment and cases with new sympt...
In a Chinese-language review published in 2008 to evaluate the validity of placebo in all herbal trials (not limited to oncology), only 77 placebo blinded clinical trials were identified [69]. Only two articles validated the comparability between the testing drug and placebo. It is also ...
The Clauss fibrinogen assay should be used in preference to a fibrinogen estimated from the optical change in the prothrombin time (PT-derived fibrinogen), as some of these methods give falsely high functional levels.68 Data to evaluate the impact of the use of VHAs on clinical outcomes in ...
Future research is necessary to evaluate the efficacy of our proposal. This would require a commitment for all doctors to approach the field of palliative care and the empathetic approach with the patient which will be an added value to their specialist clinical skills.Data...
73 Other ongoing trials evaluate the utility of AZA/VEN maintenance therapy post allogeneic HCT (VIALE-T trial; NCT04161885) or oral azacitidine (CC-486; NCT04173533).74 Outside clinical trials, no standard therapy exists in this scenario. We aim to reduce immunosuppressive therapy as rapidly ...